Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report report published on Thursday. The firm issued a hold rating on the stock.

Separately, HC Wainwright reduced their price objective on Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating for the company in a research note on Monday, April 15th.

Oncternal Therapeutics Price Performance

Shares of ONCT stock opened at $8.29 on Thursday. The firm has a market capitalization of $22.30 million, a price-to-earnings ratio of -0.61 and a beta of 1.26. The business has a fifty day moving average of $8.84 and a 200 day moving average of $8.24. Oncternal Therapeutics has a 1 year low of $5.57 and a 1 year high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last released its quarterly earnings data on Thursday, March 7th. The company reported ($3.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.09) by ($0.02). The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.17 million. Oncternal Therapeutics had a negative net margin of 5,029.17% and a negative return on equity of 95.87%. During the same quarter in the previous year, the business posted ($4.00) EPS. As a group, equities research analysts expect that Oncternal Therapeutics will post -10.67 earnings per share for the current year.

Insider Activity

In other Oncternal Therapeutics news, Director Robert James Wills bought 3,086 shares of the company’s stock in a transaction dated Monday, April 8th. The shares were purchased at an average cost of $8.96 per share, for a total transaction of $27,650.56. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $89,600. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have acquired 10,714 shares of company stock worth $92,736 in the last ninety days. Company insiders own 8.00% of the company’s stock.

Institutional Investors Weigh In On Oncternal Therapeutics

A hedge fund recently raised its stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC increased its holdings in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) by 79.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 500,000 shares of the company’s stock after acquiring an additional 221,250 shares during the period. Pasadena Private Wealth LLC owned approximately 16.96% of Oncternal Therapeutics worth $268,000 as of its most recent SEC filing. 16.05% of the stock is currently owned by hedge funds and other institutional investors.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.